Operates a tech-enabled Medicare Advantage platform. Provides customized healthcare to seniors in the United States. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 36% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.7× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 82% of them.
Analysts' average target sits 51% above today's price.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 49% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 36% a year on average.
The company sells $3.9B a year; the problem isn’t sales — it’s costs running above that number.
There is $604.2M in the vault; even if every debt were paid off, $274.6M would remain.
A loss of $724K against $3.9B in annual sales.
Over the last 12 months, executives reported 80 sells against just 22 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, ALHC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ALHC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.